HeraMED Ltd. (AU:HMD) has released an update.
HeraMED Limited has officially terminated their partnership with Fembridge after failing to renegotiate the terms of their strategic agreement, aimed at developing a maternity care solution for the US market. Despite the setback, HeraMED is forging ahead with its commercialization strategy in the USA, seeking alignment with other partners and directly engaging with hospitals and clinics to promote their maternity care platform, HeraCARE. The company remains focused on enhancing patient care and ensuring maximum shareholder value, with ongoing plans to expand in the US, Australia, and Europe.
For further insights into AU:HMD stock, check out TipRanks’ Stock Analysis page.
